Global Fibromyalgia Clinical Trial Pipeline Highlights, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 12, 2019--
The “Global Fibromyalgia Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering.
This report provides most up-to-date information on key pipeline products in the global Fibromyalgia market. It covers emerging therapies for Fibromyalgia in active clinical development stages including early and late stage clinical trials.
The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages
The report provides Fibromyalgia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes
The report provides Fibromyalgia pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Fibromyalgia pipeline products by the company.
Short-term Launch Highlights
Find out which Fibromyalgia pipeline products will be launched in the US and Ex-US till 2024.
Key Topics Covered
1. Fibromyalgia Pipeline by Stages
2. Fibromyalgia Phase 3 Clinical Trial Insights
3. Fibromyalgia Phase 2 Clinical Trial Insights
4. Fibromyalgia Phase 1 Clinical Trial Insights
5. Fibromyalgia Preclinical Research Insights
6. Fibromyalgia Discovery Stage Insights
8. Research Methodology
List of Tables
Table 1: Fibromyalgia Phase 3 Clinical Trials, 2019
Table 2: Fibromyalgia Phase 2 Clinical Trials, 2019
Table 3: Fibromyalgia Phase 1 Clinical Trials, 2019
Table 4: Fibromyalgia Preclinical Research, 2019
Table 5: Fibromyalgia Discovery Stage, 2019
List of Figures
Figure 1: Fibromyalgia Pipeline Molecules by Clinical Trials Stage, 2019
Figure 2: Fibromyalgia Phase 3 Clinical Trial Highlights, 2019
Figure 3: Fibromyalgia Phase 2 Clinical Trial Highlights, 2019
Figure 4: Fibromyalgia Phase 1 Clinical Trial Highlights, 2019
Figure 5: Fibromyalgia Preclinical Research Highlights, 2019
Figure 6: Fibromyalgia Discovery Stage Highlights, 2019
For more information about this report visit https://www.researchandmarkets.com/r/elcef7
View source version on businesswire.com:https://www.businesswire.com/news/home/20190612005576/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Clinical Trials,Musculoskeletal Disorders Drugs
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 06/12/2019 09:43 AM/DISC: 06/12/2019 09:43 AM